10月1日 - ** 药物开发商Evommune（EVMN.N）的股价在盘前交易中上涨4.9%，至8.67美元
** 该公司表示，其实验性注射药物EVO301在一项涉及70名中重度特应性皮炎（俗称湿疹）成年患者的中期临床试验中达到了主要目标
** 据称，接受EVO301治疗的患者在12周后，湿疹的严重程度和范围平均降低了55%，而接受安慰剂治疗的患者这一比例仅为22%
** 约29%的EVO301治疗组患者湿疹严重程度改善幅度达到至少75%，而安慰剂组仅为9%
** 试验期间共给药两次，分别在试验开始时和四周后；最后一次给药后，疗效在随后的八周内持续改善
** EVO301组中有10.4%的患者报告了与治疗相关的副作用，而安慰剂组为13.6%；未报告任何与治疗相关的严重或重度副作用
** 截至上一交易日收盘，EVMN今年以来累计下跌51.8%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.